| Field | Specification |
|---|---|
| Target | |
| Alternative names | Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta; GMP-PDE beta; PDE6B; PDEB |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human PDE6 beta/PDE6B recombinant protein (Position: K25-Q237). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta (gene PDE6B) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 98.3 kDa, and the supplier reports an observed band at about 98 kDa.
PDE6B is the beta catalytic subunit of rod PDE6, the effector enzyme of phototransduction. Activated transducin relieves inhibition by the PDE6 gamma subunits, so PDE6 lowers cGMP and closes cGMP-gated cation channels, producing the rod light response. PDE6B mutations cause retinitis pigmentosa, and the rd1 mouse carrying a Pde6b defect is a classic model of retinal degeneration.
| Target | Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta (gene PDE6B; UniProt P35913, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3 |
| Calculated MW | 98.3 kDa |
| Observed MW | 98 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 4 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): rat eye tissue, mouse eye tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, human rectal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells, A549 cells.
Samples with a confirmed signal (flow cytometry): U87 cells.
Immunogen
Recombinant human PDE6 beta/PDE6B fragment (Lys25–Gln237), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta in the photoreceptor outer segment membrane and membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
